Építés alatt – nem éles oldal
Belépés
Toborzás még nem indultFázis nélkül

A Prospective, Single-centre, Observational Cohort Study on the Efficacy and Safety of Bacterial Lysate (OM-85) in Combination With Antihistamines for the Treatment of Chronic Spontaneous Urticaria (CSU)

A legfontosabb adatok

Ki végzi
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
132 fő, tervezett
Kezdés
2026. máj. 1.
Várható befejezés
2027. jún. 1.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2026. május 7.

Ki vehet részt

The trial is looking for adults with chronic spontaneous urticaria (long-lasting hives with no clear outside trigger) whose symptoms are not controlled by antihistamines. It compares people taking the bacterial lysate OM-85 with antihistamines against people taking antihistamines alone.

Életkor
18 to 65 years
Nem
All sexes
A betegség stádiuma
Chronic spontaneous urticaria lasting 6 weeks or more. Symptoms still not controlled, with a UAS7 score of 7 or more in the 7 days before the screening and baseline visits.
Korábbi kezelés
A standard dose of a second-generation H1 antihistamine (for example desloratadine 5 mg, levocetirizine 5 mg) taken regularly for at least 2 weeks before screening. People must keep the same antihistamine and dose during the trial. No steroid tablets or injections, immunosuppressants or antibiotics in the last 4 weeks. No biologics, bacterial lysates or vaccinations in the last 3 months.
Biomarker vagy leletérték
UAS7 score (a weekly hives symptom score) of 7 or more.
A részvétel fő kizáró okai
  • Special types of hives, such as physical urticaria, urticarial vasculitis, or swelling from C1 esterase inhibitor deficiency
  • Severe autoimmune disease, such as lupus, rheumatoid arthritis or inflammatory bowel disease
  • History of serious liver, kidney, heart, lung or blood disease, or cancer
  • Allergy to bacterial lysates or their other ingredients
  • Pregnant or breastfeeding, or not planning to use contraception during the trial
A regiszter összes feltétele (18)A regiszter feltételeinek elrejtése

Ki vehet részt

  • The participants were fully informed of the purpose, procedure and risks of the study and voluntarily signed the informed consent form
  • Aged 18 to 65 (inclusive), no gender restrictions
  • Meets the CSU diagnostic criteria, with a disease duration of ≥6 weeks
  • Antihistamine resistance: Regular use of a standard dose (as recommended in the package leaflet) of a second-generation H1 antihistamine (e.g. desloratadine 5 mg, levocetirizine 5 mg, etc.) for at least 2 weeks prior to screening, but with symptoms still not effectively controlled. Defined as: a UAS7 score of ≥7 within 7 days prior to the screening visit (V1) and baseline visit (V2)
  • Agree to maintain the type and dose of the baseline antihistamine throughout the trial
  • Agree not to consume any products that may significantly affect the gut microbiota during the trial (such as yoghurt containing probiotics, or probiotic/prebiotic supplements)
  • At the baseline visit, the treatment regimen was clearly defined, and exposure status (OM-85 exposure group or non-exposure group) could be determined based on actual prescriptions and medication records

Ki nem vehet részt

  • Special types of urticaria: These primarily include physical urticaria (such as artificial urticaria, cold contact urticaria and cholinergic urticaria), urticarial vasculitis, and angioedema caused by hereditary or acquired C1 esterase inhibitor deficiency
  • Systemic use of glucocorticoids (oral or injectable) within the four weeks prior to screening
  • Exclude patients who have used immunosuppressants (such as cyclosporine, methotrexate, or Tripterygium wilfordii) within the previous four weeks
  • Exclude patients who have used biologics (such as omazulimab, dupilumab, etc.) within the previous three months
  • Exclude those who have used bacterial lysates (such as Panfuxu or Pidomod) or received vaccinations within the past three months
  • Key exclusion criteria for the microbiome study: use of oral or intravenous antibiotics within the four weeks prior to screening, or continuous use of probiotic supplements for more than one week
  • Patients with severe systemic autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.) may interfere with the assessment of immune mechanisms
  • A history of serious liver, kidney, heart, lung or blood disorders, or malignant tumours
  • Individuals known to be allergic to bacterial lysates and their excipients
  • Other: Participants who have taken part in other clinical trials involving medicinal products within the past 30 days; or where the investigator considers that there is poor compliance, a mental health condition, or any other circumstance rendering the participant unsuitable for the trial
  • Special populations: pregnant or breastfeeding women, or participants of childbearing age who do not intend to use contraception during the trial

Alkalmassági kérdőív

Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.

  • Életkor
  • Chronic spontaneous urticaria

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

A Prospective Clinical Study on the Efficacy and Safety of Bacterial Lysate (OM-85) Combined with Antihistamines in the Treatment of Chronic Spontaneous Urticaria (CSU): A Single-Centre, Observational, Cohort Study

A vizsgálat 2 csoportja

  • Exposure group

    Bacterial lysate capsules + second-generation antihistamines (loratadine tablets, cetirizine hydrochloride tablets, levocetirizine hydrochloride tablets, ebastine tablets, olopatadine hydrochloride tablets, fexofenadine hydrochloride tablets)

  • Non-exposure group

    Second-generation antihistamines (loratadine tablets, cetirizine hydrochloride tablets, levocetirizine hydrochloride tablets, ebastine tablets, olopatadine hydrochloride tablets, fexofenadine hydrochloride tablets)

Következő lépések

Az orvosodnak

Kérdőlap az orvosnak

PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 2 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.

A PDF letöltése

PDF, US Letter, 1–2 oldal. A4 méretben

A vizsgálati csapatnak

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective Clinical Study on the Efficacy and Safety of Bacterial Lysate (OM-85) Combined With Antihistamines in the Treatment of Chronic Spontaneous Urticaria (CSU): A Single-Centre, Observational, Cohort Study
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Kérdések a feltételekről
Forrás: NCT07557888: ki vehet részt
A regiszteradat frissítve
2026. május 7.